Real-World Assessment of Health Care Costs for Patients with Metastatic Pancreatic Cancer Following Initiation of First-Line Chemotherapy

BACKGROUND: Management of metastatic pancreatic ductal adenocarcinoma (mPDA) places a significant financial burden on the U.S. health care system because of such factors as treatment with multidrug chemotherapy regimens, management of chemotherapy-related adverse events, and disease- or treatment-re...

Descripción completa

Detalles Bibliográficos
Autores principales: Bullock, Andrea, Rowan, Christopher G., Oestreicher, Nina, Yeganegi, Homa, Chiorean, E. Gabriela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391015/
https://www.ncbi.nlm.nih.gov/pubmed/32584677
http://dx.doi.org/10.18553/jmcp.2020.26.7.872

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391015/
https://www.ncbi.nlm.nih.gov/pubmed/32584677
http://dx.doi.org/10.18553/jmcp.2020.26.7.872

Ejemplares similares